What does “Most Favoured Nation” have to do with me?
In 2025, the USA announced that it would “end global freeloading” of drug prices, reporting that despite having less than 5% of the world’s population, US citizens pay so much more for their drugs that they make up about ¾ of worldwide pharmaceutical profits. Canadians, along with people from other countries, have paid less—sometimes much less—for our drugs because pharmaceutical companies could get a good return on their research investments from the USA. The “Most Favoured Nation” (MFN) policy ends this, insisting that companies selling pharmaceuticals in the USA match the lowest international price for a drug.
This, of course, means that prices outside the USA must rise to balance pharmaceutical profits more evenly. As well, there are effects on clinical trial availability and even the willingness of companies to launch new drugs in Canada.
The Gastrointestinal Society has produced an excellent short video explaining what this means for Canadians:
You can also read their extensive information page for more information and for the references for facts mentioned in the video.
PHA Canada is working with our coalition partners to track this issue and engage with governments on solutions that can protect and enhance patient care in Canada. We’ll keep you informed!
It's eye-opening how global drug pricing policies like MFN can directly impact access and costs for Canadians. While reading about pharmaceutical equity, it reminded me that fairness in systems—whether in healthcare or technology—requires smart, adaptive solutions. For instance, just as pricing models evolve to balance fairness, tools like noisevanish.com use advanced audio filtering to clean sound fairly across all types of recordings, ensuring clearer communication for everyone.
International policy debates often sound distant until they affect the price, availability, or delivery of something people order regularly, and that made me more attentive to the service side of online health products. For a subscription-based healthcare service, I care about account setup, consultation scheduling, billing, shipment timing, privacy, and how clearly changes or cancellations are handled. I keep medical decisions separate and leave those to licensed professionals. From a customer-service perspective, I consult BlueChew reviews to understand ordering and subscription experiences without turning personal treatment outcomes into advice. That distinction matters because a smooth account process and a medical result are not the same thing. I want reviews to stay clear about which part of the experience they are describing.
When reading about trade policies like MFN and shifting economic standards, I see how external factors quietly push up local service costs. The same dynamic affects education, where top qualifications command high rates unless remote delivery reduces overhead. If you want to compare rates, an etobicoke music school provides remote options with Juno nominees and RCM award winners. Higher credentials never guarantee a good fit, so evaluating value objectively is always advisable
The information about lipoprotein https://ways2well.com/blog/cholesterol-and-plasmapheresis-how-the-treatment-works was one of the most interesting parts of this article for me. It explains why apheresis has been studied in people with very high Lp(a) levels and progressive cardiovascular disease. The article also describes the difference between removing plasma itself and selectively targeting LDL and Lp(a) particles. I found the explanation of why treatments may need to be repeated every one or two weeks helpful for understanding the practical side of this therapy
Thank you for such an insightful post on the "Most Favoured Nation" concept. It reminds me of my experience navigating Skribbl IO, where understanding regional advantages can make all the difference in competitive play. Your explanations really resonated with me!